首页> 外文期刊>BMC Surgery >The Anal Fistula Plug versus the mucosal advancement flap for the treatment of Anorectal Fistula (PLUG trial)
【24h】

The Anal Fistula Plug versus the mucosal advancement flap for the treatment of Anorectal Fistula (PLUG trial)

机译:肛瘘塞与粘膜推进瓣治疗肛肠瘘(PLUG试验)

获取原文
           

摘要

Background Low transsphincteric fistulas less than 1/3 of the sphincter complex are easy to treat by fistulotomy with a high success rate. High transsphincteric fistulas remain a surgical challenge. Various surgical procedures are available, but recurrence rates of these techniques are disappointingly high. The mucosal flap advancement is considered the gold standard for the treatment of high perianal fistula of cryptoglandular origin by most colorectal surgeons. In the literature a recurrence rate between 0 and 63% is reported for the mucosal flap advancement. Recently Armstrong and colleagues reported on a new biologic anal fistula plug, a bioabsorbable xenograft made of lyophilized porcine intestinal submucosa. Their prospective series of 15 patients with high perianal fistula treated with the anal fistula plug showed promising results. The anal fistula plug trial is designed to compare the anal fistula plug with the mucosal flap advancement in the treatment of high perianal fistula in terms of success rate, continence, postoperative pain, and quality of life. Methods/design The PLUG trial is a randomized controlled multicenter trial. Sixty patients with high perianal fistulas of cryptoglandular origin will be randomized to either the fistula plug or the mucosal advancement flap. Study parameters will be anorectal fistula closure-rate, continence, post-operative pain, and quality of life. Patients will be followed-up at two weeks, four weeks, and 16 weeks. At the final follow-up closure rate is determined by clinical examination by a surgeon blinded for the intervention. Discussion Before broadly implementing the anal fistula plug results of randomized trials using the plug should be awaited. This randomized controlled trial comparing the anal fistula plug and the mucosal advancement flap should provide evidence regarding the effectiveness of the anal fistula plug in the treatment of high perianal fistulas. Trial registration ISRCTN: 97376902
机译:背景技术经括约肌切开术易于治疗括约肌复杂性的不到1/3的低括约肌瘘,成功率很高。高括约肌瘘仍然是外科手术的挑战。可以使用各种外科手术程序,但是这些技术的复发率高得令人失望。大多数结肠直肠外科医师认为粘膜瓣的进展是治疗隐腺源性高肛周瘘管的金标准。在文献中,据报道粘膜皮瓣进展的复发率为0%至63%。最近,阿姆斯特朗及其同事报道了一种新的生物肛门瘘塞,一种由冻干猪肠粘膜下层制成的可生物吸收的异种移植物。他们对15例肛瘘高位肛瘘患者进行了前瞻性研究,结果令人满意。肛瘘塞试验旨在比较肛瘘塞与粘膜瓣进展在成功治疗肛周瘘管方面的成功率,节制,术后疼痛和生活质量。方法/设计PLUG试验是一项随机对照的多中心试验。 60例隐性腺源性高肛周瘘管患者将被随机分配至瘘管塞或粘膜进展性皮瓣。研究参数将是肛肠瘘的闭合率,尿失禁,术后疼痛和生活质量。将在两周,四周和十六周对患者进行随访。在最后的随访中,封闭率由对干预不知情的外科医生通过临床检查确定。讨论在广泛实施肛瘘插塞之前,应等待使用插塞的随机试验结果。这项比较肛瘘塞和黏膜前移瓣的随机对照试验应提供有关肛瘘塞在治疗高位肛周瘘管中有效性的证据。试用注册ISRCTN:97376902

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号